This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:1279-1281.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

CHICAGO—As the HIV/AIDS epidemic approaches the 20th anniversary of the first mysterious reports of people with the syndrome, researchers and clinicians continue to grapple with the complexities of the virus.

Those complexities were readily evident here at the 8th Annual Retrovirus Conference, where some 3000 participants gathered to hear reports of the latest findings.

Although at least 15 drugs have been approved to treat HIV infection and experimental therapies are in the developmental pipeline, new reports of rising resistance rates—as well as a better appreciation of potential adverse effects—underscore the urgent need for new antiretroviral agents. At the same time, discoveries about the molecular underpinnings of HIV and the genetic makeup of people infected with the virus are providing fresh insights into variations in risk for complications involving anti-HIV drugs and for disease associated with HCV coinfection.

DRUG-RESISTANT HIV

Although drug-resistant HIV has been an important . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Cost Effectiveness of Antiretroviral Therapy for HIV Disease
Messori et al.
NEJM 2001;345:68-69.
FULL TEXT